Claudin-9 (CLDN9) promotes gastric cancer progression by enhancing the glycolysis pathway and facilitating PD-L1 lactylation to suppress CD8+ T cell anti-tumor immunity

• Published in: Cancer pathogenesis and therapy Vol. 3; no. 3; pp. 253 - 266
• Main Authors: Hu, Xingbin, Ouyang, Wenhao, Chen, Haizhu, Liu, Zhihong, Lai, Zijia, Yao, Herui
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.05.2025; Elsevier
• Subjects: CLDN9; Gastric cancer; Glycolysis; Immune evasion; Lactylation; PD-L1; Glycolysis; PD-L1; Immune evasion; CLDN9; Gastric cancer; Lactylation

Gastric cancer (GC) is a common malignancy characterized by the absence of reliable prognostic indicators and effective therapeutic targets. Claudin-9 (CLDN9) has been demonstrated to be upregulated in various cancers. However, its prognostic value, biological function, and regulatory mechanisms in...